MARKET

SGMOQ

SGMOQ

Sangamo Therapeutics Inc
OTCPK
0.160
+0.014
+9.36%
Closed 15:54 08/24 EDT
OPEN
0.150
PREV CLOSE
0.146
HIGH
0.167
LOW
0.146
VOLUME
1.57M
TURNOVER
252.98K
52 WEEK HIGH
0.766
52 WEEK LOW
0.030
MARKET CAP
66.29M
P/E (TTM)
-0.4180
1D
5D
1M
3M
1Y
5Y
1D
Sangamo Therapeutics Delays Quarterly 10-Q Filing
TipRanks · 08/17 22:17
Weekly Report: what happened at SGMOQ last week (0810-0814)?
Weekly Report · 08/17 09:02
Sangamo Concludes Section 363 Asset Sales in Bankruptcy
TipRanks · 08/13 10:33
Press Release: Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones
Dow Jones · 08/12 20:45
Sangamo Therapeutics Reports Post-Bankruptcy Operating Developments
TipRanks · 08/12 20:36
Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones
Barchart · 08/12 15:01
Weekly Report: what happened at SGMOQ last week (0803-0807)?
Weekly Report · 08/10 09:02
Weekly Report: what happened at SGMOQ last week (0727-0731)?
Weekly Report · 08/03 09:02
More
About SGMOQ
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.

Webull offers Sangamo Therapeutics Inc stock information, including OTCPK: SGMOQ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMOQ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMOQ stock methods without spending real money on the virtual paper trading platform.